Country: Canada
Language: English
Source: Health Canada
MONTELUKAST (MONTELUKAST SODIUM)
AURO PHARMA INC
R03DC03
MONTELUKAST
4MG
TABLET (CHEWABLE)
MONTELUKAST (MONTELUKAST SODIUM) 4MG
ORAL
10/30
Prescription
LEUKOTRIENE MODIFIERS
Active ingredient group (AIG) number: 0133823003; AHFS:
APPROVED
2014-03-25
_ _ _ _ _Page 1 of 34 _ PRODUCT MONOGRAPH PR AURO-MONTELUKAST CHEWABLE TABLET montelukast (as montelukast sodium) 4 mg and 5 mg chewable tablets Leukotriene Receptor Antagonist AURO PHARMA INC. Date of Revision: 3700 Steeles Avenue West, Suite # 402 November 10, 2020 Woodbridge, Ontario, L4L 8K8 CANADA SUBMISSION CONTROL NO.: 244280 _ _ _ _ _Page 2 of 34 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .....................................................3 SUMMARY PRODUCT INFORMATION........................................................................ 3 INDICATIONS AND CLINICAL USE............................................................................. 3 CONTRAINDICATIONS................................................................................................... 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 7 DRUG INTERACTIONS ................................................................................................. 10 DOSAGE AND ADMINISTRATION............................................................................. 11 OVERDOSAGE................................................................................................................ 13 ACTION AND CLINICAL PHARMACOLOGY............................................................ 13 STORAGE AND STABILITY......................................................................................... 17 DOSAGE FORMS, COMPOSITION AND PACKAGING............................................. 17 PART II: SCIENTIFIC INFORMATION.......................................................................... 18 PHARMACEUTICAL INFORMATION ......................................................................... 18 CLINICAL TRIALS ......................................................................................................... 18 TOXICOLOGY..................... Read the complete document